Intermittent Treatment of BRAFV600E Melanoma Cells Delays Resistance by Adaptive Resensitization to Drug Rechallenge

By
Justin.choi
-
0
38
Investigators showed that intermittent treatment with the BRAFV600E inhibitor, LGX818/encorafenib, suppressed growth compared with continuous treatment in human melanoma cells engineered to express BRAFV600E, p61-BRAFV600E, or MEK2C125 oncogenes.
[Proceedings of the National Academy of Sciences of the United States of America]
Abstract